Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q92743
UPID:
HTRA1_HUMAN
Alternative names:
High-temperature requirement A serine peptidase 1; L56; Serine protease 11
Alternative UPACC:
Q92743; D3DRE4; Q9UNS5
Background:
Serine protease HTRA1, also known as High-temperature requirement A serine peptidase 1, plays a critical role in various biological processes. It targets extracellular matrix proteins like fibronectin, degrades proteoglycans such as aggrecan, and regulates insulin-like growth factors by cleaving IGF-binding proteins. Its activity against TGF-beta signaling is crucial for physiological processes including retinal angiogenesis and neuronal survival.
Therapeutic significance:
HTRA1's involvement in diseases such as age-related macular degeneration and cerebral arteriopathy highlights its potential as a therapeutic target. Understanding the role of Serine protease HTRA1 could open doors to potential therapeutic strategies for these conditions, offering hope for treatments that could alleviate symptoms or slow disease progression.